From GlobeNewswire:

The PARP Inhibitor Market is valued at USD 12.5 Billion in 2024 and is projected to reach USD 67.0 Billion by 2034, with a CAGR of 18.30%. These inhibitors disrupt cancer cell repair mechanisms and show promise in treating various cancers, expanding treatment options and driving market growth. Innovation and biomarker testing advancements are shaping the market dynamics. Regional analysis indicates North America as a key market due to regulatory approvals and adoption of PARP inhibitors. Innovations in bio-based materials like PARP Inhibitors are driven by sustainability concerns and offer versatile properties for various industries. Ongoing R&D efforts focus on advancing production technologies and enhancing product performance in the PARP Inhibitor sector.



Read more at GlobeNewswire: PARP Inhibitor Market to Surpass USD 67.0 Billion by 2034,